Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Research & Development (2022 - 2025)

BioXcel Therapeutics has reported Research & Development over the past 4 years, most recently at $6.7 million for Q4 2025.

  • Quarterly results put Research & Development at $6.7 million for Q4 2025, up 13.56% from a year ago — trailing twelve months through Dec 2025 was $30.3 million (down 0.6% YoY), and the annual figure for FY2025 was $30.3 million, down 0.6%.
  • Research & Development for Q4 2025 was $6.7 million at BioXcel Therapeutics, down from $8.7 million in the prior quarter.
  • Over the last five years, Research & Development for BTAI hit a ceiling of $32.5 million in Q4 2022 and a floor of $4.6 million in Q1 2025.
  • Median Research & Development over the past 4 years was $10.8 million (2024), compared with a mean of $14.7 million.
  • Biggest five-year swings in Research & Development: tumbled 74.0% in 2024 and later skyrocketed 71.34% in 2025.
  • BioXcel Therapeutics' Research & Development stood at $32.5 million in 2022, then crashed by 69.4% to $9.9 million in 2023, then tumbled by 40.6% to $5.9 million in 2024, then rose by 13.56% to $6.7 million in 2025.
  • The last three reported values for Research & Development were $6.7 million (Q4 2025), $8.7 million (Q3 2025), and $10.3 million (Q2 2025) per Business Quant data.